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Abstract
Objectives This study aims to define consensus-based criteria for acquiring and reporting prostate MRI and establishing prereq-
uisites for image quality.
Methods A total of 44 leading urologists and urogenital radiologists who are experts in prostate cancer imaging from the
European Society of Urogenital Radiology (ESUR) and EAU Section of Urologic Imaging (ESUI) participated in a Delphi
consensus process. Panellists completed two rounds of questionnaires with 55 items under three headings: image quality
assessment, interpretation and reporting, and radiologists’ experience plus training centres. Of 55 questions, 31 were rated for
agreement on a 9-point scale, and 24 were multiple-choice or open. For agreement items, there was consensus agreement with an
agreement ≥ 70% (score 7–9) and disagreement of ≤ 15% of the panellists. For the other questions, a consensus was considered
with ≥ 50% of votes.
Results Twenty-four out of 31 of agreement items and 11/16 of other questions reached consensus. Agreement statements were
(1) reporting of image quality should be performed and implemented into clinical practice; (2) for interpretation performance,
radiologists should use self-performance tests with histopathology feedback, compare their interpretation with expert-reading and
use external performance assessments; and (3) radiologists must attend theoretical and hands-on courses before interpreting
prostate MRI. Limitations are that the results are expert opinions and not based on systematic reviews or meta-analyses. There
was no consensus on outcomes statements of prostate MRI assessment as quality marker.
Conclusions An ESUR and ESUI expert panel showed high agreement (74%) on issues improving prostate MRI quality.
Checking and reporting of image quality are mandatory. Prostate radiologists should attend theoretical and hands-on courses,
followed by supervised education, and must perform regular performance assessments.
Key Points
• Multi-parametric MRI in the diagnostic pathway of prostate cancer has a well-established upfront role in the recently updated
European Association of Urology guideline and American Urological Association recommendations.
• Suboptimal image acquisition and reporting at an individual level will result in clinicians losing confidence in the technique
and returning to the (non-MRI) systematic biopsy pathway. Therefore, it is crucial to establish quality criteria for the acqui-
sition and reporting of mpMRI.
• To ensure high-quality prostate MRI, experts consider checking and reporting of image quality mandatory. Prostate radiol-
ogists must attend theoretical and hands-on courses, followed by supervised education, and must perform regular self- and
external performance assessments.
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ESUR European Society of Urogenital Radiology
MDT Multidisciplinary team
mpMRI Multi-parametric MRI
PCa Prostate cancer
Q Question
TRUSGB Transrectal ultrasound–guided biopsy
Introduction
Multi-parametric MRI (mpMRI) in the diagnostic pathway of
prostate cancer (PCa) has a well-established upfront role in the
recently updated European Association of Urology (EAU)
guideline and American Urological Association recommenda-
tions [1, 2]. For biopsy-naïve men with suspicion of PCa,
based on an elevated serum prostate–specific antigen level
or abnormal digital rectal examination, it is now recommend-
ed to undergo a mpMRI before biopsy. Incorporation of
mpMRI in the diagnostic pathway of men with clinical suspi-
cion of PCa has several advantages compared to a systematic
transrectal ultrasonography–guided biopsy (TRUSGB) ap-
proach. MRI can rule out clinically significant (cs)PCa and,
therefore, will result in fewer unnecessary prostate biopsies
[3–5]. Also, mpMRI reduces overdiagnosis and overtreatment
of low-grade cancer [5–9]. Finally, mpMRI allows targeted
biopsies of those lesions assessed as suspicious, enabling bet-
ter risk stratification [10].
If one wants to take advantage of the ‘MRI pathway’, an-
nually 1,000,000 men in Europe need to have a pre-biopsy
MRI [11]. Performing such a high number of mpMRIs with
high-quality acquisition and high-quality reporting is a signif-
icant challenge for the uroradiological community.
Fortunately, the recently updated Prostate Imaging-
Reporting and Data System (PI-RADS) version 2.1 defines
global standardization of reporting and recommends uniform
acquisition [12]. However, there is a lack of consensus on how
to assure and uphold mpMRI acquisition and reporting qual-
ity. There is also a need to define requirements for learning
and accumulation of reporting experience for mpMRI.
Suboptimal image acquisition and reporting at an individ-
ual level will result in clinicians losing confidence in the tech-
nique and returning to the (non-MRI) TRUS biopsy pathway.
Therefore, it is crucial to establish quality criteria for both
acquisition and reporting of mpMRI. Thus, this study aims
to define consensus-based criteria for acquiring and reporting
mpMRI scans and determining the prerequisites for mpMRI
quality.
Materials and methods
A Delphi consensus process was undertaken to formulate rec-
ommendations regarding three different areas in the diagnostic
MRI pathway of PCa: (1) image quality assessment of
mpMRI; (2) interpretation and reporting of mpMRI; and (3)
reader experience and training requirements. The Delphi
method is a technique of structured and systematic informa-
tion gathering from experts on a specific topic using a series of
questionnaires [13]. In this study, the diagnostic role of
mpMRI in biopsy-naïve men with a suspicion of PCa was
considered.
The Delphi process was carried out in four phases (Fig. 1).
(1) Panellists from the European Society of Urogenital
Radiology (ESUR) and EAU Section of Urologic Imaging
(ESUI) were selected based on expertise and publication re-
cord in the PCa diagnosis, and on their involvement in guide-
line development. (2) A questionnaire was created with items
that were identified by a subcommittee of the ESUR, based on
the statements from a recent UK consensus paper on imple-
mentation of mpMRI for PCa detection [14]. (3) Panel-based
consensus findings were determined using an online Delphi
process. For this purpose, an internet survey was generated
and sent by email to the members of the group (created in
Google Forms). In the second round, a reminder to complete
the questionnaires was sent by email. The panellists anony-
mously completed two rounds of a questionnaire consisting of
39 items (including 55 subquestions). Based on the knowl-
edge of the entire group’s responses in the first round, second
round voting was performed. Outcomes of the multiple-choice
and open questions were graphically displayed, so the results
could be reflected before selecting a response in the second
round. For inclusion in the final recommendations, each sur-
vey item required to have reached group consensus by the end
of the two survey rounds. (4) The items of the questionnaires
were analysed, and consensus statements were formulated
based on the outcomes. In total, 31 of 55 items were rated
for agreement on a 9-point Likert scale.
An item scored as ‘agree’ (score 7–9) by ≥ 70% of partic-
ipants and disagree (score 1–3) by ≤ 15% constituted ‘consen-
sus agreement’ for an item. An item scored as ‘disagree’
(score 1–3) by ≥ 70% of participants and agree (score 7–9)
by ≤ 15% was considered as ‘consensus disagreement’. The
other items (24 of 55) were multiple-choice or open questions
and were presented graphically. For the multiple-choice or
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open questions to reach consensus, a panel majority scoring of
≥ 50% was required.
Results
The response rate for both rounds was 58% (44 of 76). The
final panel comprised 44 urologists and urogenital radiologists
who are experts in prostate cancer imaging. After the first
round, eight subquestions were deleted based on comments
from the panellists in the free-text fields because they consid-
ered these items either a duplication or not relevant (questions:
8b, 9b, 10b, 16c, 16d, 19b, 26b, 32b; Tables 1, 2 and 3). All
deleted subquestions were questions without consensus in the
first round.
After the first round of the Delphi process, consensus
agreement was obtained in 19 of 31 (61%) questions that
could be rated on a 1–9 scale. Consensus was obtained in 1
of 24 (4.2%) of multiple-choice/open questions. After the sec-
ond round, this improved to 24 of 31 (77%) and in 11 of 16
(69%), respectively. None of the statements received consen-
sual disagreement. Agreement statements combined with the
outcomes of the multiple-choice/open questions were used to
provide input for the recommendations regarding image
quality and learning of prostate mpMRI and expertise of
(training) centres (Tables 4 and 5).
Section 1: Image quality assessment
The panellists consensually agreed on all five agreement state-
ments in this section (Table 1). Consensus was reached on 2
out of 3 multiple-choice questions. Assessment of the techni-
cal image quality measures should be checked (question (Q)1)
and reported (Q2), which can be qualitatively done by visual
assessments by radiologists (Q5). Checking image quality is
realistic and should be implemented into clinical practice
(Q3). A majority of the panellists voted for external and ob-
jective image quality assessment regularly at 6 months or lon-
ger intervals (70%; 31 of 44 panellists). There was no consen-
sus on whether image quality assessment was to be performed
after a set number of cases, and panellists chose an interval of
300 or ≥ 400 cases in 25% (11 of 44 panellists) and 41% (18 of
44), respectively. Image quality checks could also be per-
formed on a randomly selected sample of cases, wherein a
majority (64%; 28 of 44 panellists) agreed that a selection of
5% of exams is most appropriate, but commented this could
be dependent on the number of cases per centre.
Furthermore, the use of a standardized phantom for appar-
ent diffusion coefficient value measurements is advocated
Fig. 1 Details of the stages of the
Delphi process (flow chart)
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(Q4), to enable quantifiable apparent diffusion coefficient
(ADC) values that could be used as a threshold for the detec-
tion of csPCa in the peripheral zone.
Section 2: Interpretation and reporting of mpMRI
The panellists have reached a consensus on 5/10 statements in
this section (Table 2). There was no consensus on the
multiple-choice questions in this section.
There was agreement on the use of self-performance tests
to evaluate a radiologists’ performance (Q8a). Panellists did
not agree upon the ideal frequency for this evaluation (Q8b;
only answered in round 1). Consensus was reached onmaking
use of histopathologic feedback, which is mandatory to eval-
uate the radiologists’ interpretation performance (Q11). Also,
consensus was reached; comparing the radiologists’ perfor-
mance to expert-reading (Q12), the use of external perfor-
mance assessments (Q9a), and the use of internet-based his-
tologically validated cases (Q13) should be part of the quality
Table 1 ESUR/ESUI consensus outcomes for section 1: Image quality assessment of mpMRI. ADC apparent diffusion coefficient, ESUI EAU
Section of Urologic Imaging, ESUR European Society of Urogenital Radiology, mpMRI multi-parametric MRI, N/A not applicable
SECTION 1 Image-quality assessment of mpMRI Round 1 Round 2 Round 2:
% Agreement 
1. Checking image-quality could improve mpMRI 
reproducibility. 
Consensus 
agreement
Consensus 
agreement 95%
2. Reporng the image-quality should be performed. Consensus 
agreement
Consensus 
agreement 89%
3. Checking the image-quality is realisc and should be 
implemented in pracce.
Consensus 
agreement
Consensus 
agreement 98%
4. We should work on a standardized phantom for ADC 
measurements.
No 
consensus
Consensus 
agreement 84%
5. Visual image assessment by a radiologist analyzing the 
images is adequate enough to determine diagnosc 
acceptability.
No 
consensus
Consensus 
agreement 77%
6a. Image-quality Control should be performed: Regularly at 1, 
or 2, or 3, or 4, or ≥6 monthly intervals?
No 
consensus
Consensus:
≥6 monthly
70%
6b. Image-quality Control should be performed: Regularly 
every 100, or 200, or 300, or 400 cases?
No 
consensus
No 
consensus N/A
6c. Image-quality Control should be performed: Randomly 
select 5% or 10% of studies
No 
consensus
Consensus:
5%
64%
Agreement statement
Mulple-choice/open queson
Consensus (agreement; ≥70% agree (score 7-9) and ≤15% disagree (score 1-3))
No consensus 
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Table 2 ESUR/ESUI consensus outcomes for section 2: Interpretation and reporting of mpMRI. ADC apparent diffusion coefficient, ESUI EAU
Section of Urologic Imaging, ESUR European Society of Urogenital Radiology, mpMRI multi-parametric MRI, N/A not applicable
I Round 1 Round 2 Round 2:
% Agreement
7. To evaluate interpr e- e 
no further tests is enough. No consensus No consensus 64%
8a. To evaluate interpreta n performance, 
radiologists should use self-performance tests. No consensus
Consensus
agreement
86%
8b. What would be the ideal frequency? No consensus N/A N/A
9. To evaluate the radiolo
performance, external performance assessments 
should be done.
No consensus
Consensus
agreement
73%
9b. What would be the ideal frequency? No consensus N/A N/A
10a. To evaluate the radiologists’ performance, 
-based audits should be done. No consensus No consensus 66%
10b. What would be the ideal frequency? No consensus N/A N/A
11. To evaluate the radiologists’ interpr
performance, histopathologic feedback is mandatory.
Consensus 
agreement
Consensus 
agreement 98%
12. Assessment should be performed by comparing
the radiologists’ performance to expert reading. No consensus
Consensus 
agreement 75%
13. Assessment should be performed by using 
histology-validated cases by internet (like breast MRI:
uk/).
Consensus 
agreement
Consensus 
agreement 98%
14. There should be an oblig
with MRI and histology. No consensus No consensus 55%
15a. The percentage of neg pMRI (PI-RADS 1-2)
should be monitored as a marker of the quality of 
on performance.
No consensus No consensus 55%
15b. If your score is 7-9, please indicate: the number 
of PI-RADS 1-2 diagnoses should be at least .. % No consensus No consensus N/A
16a. The percentage of lesions scored PI-RADS3, PI-
RADS4 and PI-RADS5 should be monitored as a 
mark
No consensus No consensus 52%
Agreement statement
Consensus (agreement; ≥70% agree (score 7-9) and ≤15% disagree (score 1-3))
No consensus
16b. If your score is 7-9, please indicate: the number 
of PI-RADS 3 diagnoses should be maximum of .. % No consensus No consensus N/A
16c. If your score is 7-9, please indicate: the number 
of PI-RADS 4 diagnoses should be at least .. % No consensus N/A N/A
16d. If your score is 7-9, please indicate: the number 
of PI-RADS 5 diagnoses should be at least .. % No consensus N/A N/A
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Table 3 ESUR/ESUI consensus outcomes for section 3: Experience and training centres. ESUI EAU Section of Urologic Imaging, ESUR European
Society of Urogenital Radiology, MDT multidisciplinary team, mpMRI multi-parametric MRI, N/A not applicable
SECTION 3 Experience and training centres Round 1 Round 2 Round 2: 
% Agreement
17. Before interpreng prostate mpMRI, 
radiologists should receive a training.
Consensus 
agreement
Consensus 
agreement 100%
18. Radiologists should undertake a combinaon of 
core theorecal prostate mpMRI courses and 
hands-on pracce at workstaons with supervised 
reporng 
Consensus 
agreement
Consensus 
agreement 98%
19a. Radiologists should parcipate in MDT 
meengs or aend MDT-type workshops where 
paent-based clinical scenarios are discussed.
Consensus 
agreement
Consensus 
agreement 98%
19b. How many MDT per year should be aended? No consensus N/A N/A
20. The MDT must include MRI review with 
histology results from targeted biopsy, 
prostatectomy.
Consensus 
agreement
Consensus 
agreement 95%
21. The MDT must include urology, radiology, 
pathology, medical- and radiaon oncology.
Consensus 
agreement
Consensus 
agreement 86%
22. Prostate radiologists should compare their 
performance with histopathological feedback.
Consensus 
agreement
Consensus 
agreement 100%
23. Prostate radiologists should have role in 
(shared-) decision making to targeted biopsies.
Consensus 
agreement
Consensus 
agreement 95%
24. Prostate radiologists should have knowledge of 
added value of MRI and consequences of false 
posive MRI.
Consensus 
agreement
Consensus 
agreement 100%
25. Prostate radiologists should be aware of 
alternave diagnosc methods (risk straficaon in 
diagnosc/treatment work-up). 
Consensus 
agreement
Consensus 
agreement 98%
26a. Training should be cerfied. Consensus 
agreement
Consensus 
agreement 93%
26b. By what organizaon? No consensus N/A N/A
27. How many cases supervised reporng should be 
done, before independent reporng? No consensus
Consensus:
100 cases
57%
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28a. Beginning radiologists should have read: Consensus
400 cases
Consensus:
400 cases
93%
28b. Expert radiologists should have read: No consensus Consensus: 1000 cases 77%
29a. Beginning radiologists should be carrying out a 
minimum number of: No consensus
Consensus:
150 cases/year
52%
29b. Expert radiologists should be carrying out a 
minimum number of: No consensus No consensus N/A
30a. Beginning radiologists should perform an 
No consensus
Consensus:
1 year
57%
30b. Expert radiologists should perform an 
No consensus
Consensus:
4 years
75%
31a. Beginning radiologists should have at least ..% 
agreement in Double Reads with an expert training 
centre.
No consensus
Consensus:
80%
52%
31b. Expert radiologists should have at least ..% 
agreement in Double Reads with an expert training 
centre.
No consensus Consensus: ≥90% 64%
32a. There should be several levels of knowledge 
skills for prostate radiologists? No consensus No consensus 41%
32b. If yes, how many? E.g.: Basic (beginning), 
independent reading with clinical (sub-specialty) 
level, top-level (reference centre)
No consensus N/A N/A
33. For good prostate MRI quality, assessment of 
the technical quality measures should be in place. 
Consensus 
agreement
Consensus 
agreement 95%
34. Minimal technical requirements of PI-RADS v2 
should be met. 
Consensus 
agreement
Consensus 
agreement 100%
35. A peer review of image-quality should be 
organized.
Consensus 
agreement
Consensus 
agreement 80%
36. Double read should be performed. No consensus No consensus 39%
37. PI-RADS should be used as basic assessment Consensus 
agreement
Consensus 
agreement 98%
38. Hands-on training may be given by high 
throughput centres that perform: No consensus
Consensus:
500 cases/year
50%
No consensus No consensus N/A
high throughput centres that perform
Agreement statement
Consensus (agreement; ≥70% agree (score 7-9) and ≤15% disagree (score 1-3))
No consensus 
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assessment, to improve individual radiologists’ skill at
interpretation.
There was no consensus on using institution-based audits
as part of the quality assessment on acquisition and reporting
(Q10a). Also, there was no consensus on the use of a percent-
age of non-suspicious mpMRI (PI-RADS 1 or 2) as a marker
for the quality of reporting (Q15a); the use of a percentage of
PI-RADS 3, 4 or 5 as a marker for the quality of interpretation
(Q16a); and on the questions about monitoring the percent-
ages of PI-RADS 1–2 (non-suspicious), 3 (equivocal) or 4–5
(suspicious) lesions as markers for the quality of scan inter-
pretations.Multiple panellists commented that the percentages
in Q15 and Q16 are highly dependent on the prevalence of
csPCa in the population at risk. There was no agreement on
impelling a database with MRI and correlative histology man-
datory (Q14).
Section 3: Experience and training centres
This section comprised questions regarding general require-
ments for radiologists who interpret prostate mpMRI and
statements on knowledge levels and experience (Table 3).
Consensus was reached on 14 out of 16 agreement statements
(88%) and 9 out of 11 multiple-choice/open questions (82%).
General requirements
Before independently reading prostate mpMRI, radiologists
should undertake a combination of core theoretical prostate
mpMRI courses with lectures on the existing knowledge
about prostate cancer (imaging) and hands-on practice at
workstations where experts supervise reporting (Q17). The
panellists agreed upon certification of training (Q26a).
However, there was no consensus on what body (national or
European) should be the certifying organization (Q26b). For
good prostate mpMRI quality, assessment of the technical
quality measures should be in place (Q33), and minimal tech-
nical requirements according to PI-RADS v2 should be met
(Q34). Panellists agreed that peer reviews of image quality
should be organized (Q35). PI-RADS should be used as a
basic assessment tool (Q37). There was no consensus about
impelling double-reading (Q36).
A prerequisite for radiologists who interpret and report
prostate mpMRI should be that they participate in the multi-
disciplinary team (MDT) meetings or attendMDT-type work-
shops where patient-based clinical scenarios are discussed
(Q19a). There was no agreement on the number of MDT
meetings that should be attended per year. An MDT must
include mpMRI review with histology results from the biopsy
and, if performed, radical prostatectomy specimens (Q20) and
presence of representatives from the urology, radiology, pa-
thology and medical and radiation oncology departments
(Q21). Prostate radiologists should have roles in the MDT in
shared decision-making on (how to perform) targeted biopsy
(Q23). Within this MDT, they should be aware of alternative
diagnostic methods (risk stratification algorithms in diagnostic
and treatment work-up) (Q25). Prostate radiologists should
know the added value of mpMRI and the consequences of
false positive or false negative mpMRI (Q24).
Knowledge levels
There was no consensus about introducing several knowledge
levels for prostate radiologists (Q32a), for instance, general
(basic), good clinical (subspeciality) and top-level (reference
centre). The panellists answered multiple-choice questions
about the experience requirements for ‘basic’ versus ‘expert’
prostate radiologists and reached consensus on 8 out of 9
(sub)questions (see Table 4).
Novice prostate radiologists should begin with supervised
reporting. A majority of the panellists favoured supervised
reporting for at least 100 cases before independent reporting
(57%; 25 of 44 panellists). In total, novice prostate radiolo-
gists should have read 400 cases to qualify as a ‘basic prostate
radiologist’ (93%; 41 of 44 panellists). They should be carry-
ing out a minimum of 150 cases/year (52%; 23 of 44
panellists) and perform an examination every year (57%; 25
of 44 panellists). In double-reads, basic prostate radiologists
should have at least 80% agreement with an expert training
centre read (52%; 23 of 44 panellists) on the assessment of PI-
RADS 1–2 versus 3–5 lesions.
Table 4 Consensus-based criteria ‘basic’ versus ‘expert’ radiologists. N/A not applicable
Basic Criterion Expert
100 Minimum number of supervised cases before independent reporting N/A
400 Minimum number of cases read 1000
150 Minimum number of cases/year 200*
1 Examination interval (year(s)) 4
80 Agreement in double reads with expert centre (%) ≥ 90
*No panel majority (most frequent answer 200 cases/year [41%; 18 of 44 panellists]; second most frequent answer was ≥ 500 cases/year [32%; 14 of 44
panellists])
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Expert prostate radiologists should have read at least 1000
cases (77%; 34 of 44 panellists). There was no consensus on
how many exams an expert radiologist should read annually.
Eighteen of 44 (41%) panellists favoured 200 cases/year,
while 14 out of 44 (32%) panellists thought that expert radi-
ologists should be carrying out a minimum of 500 cases/year.
Expert radiologists should perform an examination every
4 years (75%; 33 of 44 panellists). They should have at least
90% agreement with an expert training centre read (64%; 28
of 44 panellists).
Fifty percent of the panellists (22 of 44 panellists) voted for
at least 500 cases a year to give hands-on training. There was
no consensus on the required number of cases per year a high-
throughput centre should perform before being able to orga-
nize educational courses.
Discussion
There is a lack of evidence on how to assess prostate mpMR
image quality and on the requirements for those reading the
examinations, including learning and experience prerequisites
for independent reporting. This Delphi consensus documented
by expert radiologists and expert urologists from the ESUR
and the ESUI provides a set of recommendations to address
these issues. They are offered as a starting point to improve the
acquisition and reporting quality of mpMR images.
Three headings summarize the outcomes: (1) image quality
assessment, (2) interpretation and reporting and (3) experience
and training centres.
Image quality assessment
There is a considerable variation in prostate MR image quality
and compliance with recommendations on acquisition parame-
ters. In a recent UK quality audit, 40% of patients did not have a
prostate MRI that was adequate for interpretation, with a 38–
86% compliance variation with recognized acquisition stan-
dards [12, 15–17]. The panellists agreed that reporting of image
quality must be performed and implemented into clinical prac-
tice. Checking image quality was expected to improve mpMRI
reproducibility. Before translating these recommendations into
clinical practice, efforts are needed to develop qualitative and
preferably also quantitative criteria to assess image quality.
Interpretation and reporting
The panellists reached consensus on using self-performance
tests, with histopathologic feedback, preferably compared to
expert reading as well as to external performance assessments
to determine individual radiologists’ reporting accuracy. A
lower level of PI-RADS 3 cases (indeterminate probability
of csPCa) is seen in expert centres compared to non-expert
centres in biopsy-naïve men [7, 18]. However, the panel did
not reach consensus on the use of cut-off levels for the various
PI-RADS categories (1–2, 3 and 4–5). Aminority of panellists
favoured the use of a percentage as an indicator for the inter-
pretation quality; most of them suggested a minimal PI-RADS
1–2 percentage of 20%, a maximumPI-RADS 3 percentage of
20–30% and a minimum percentage of PI-RADS 4 and PI-
RADS 5 of 20–30% each. The high dependence of the PI-
RADS distribution on the prevalence of csPCa is the reason
for this lack of consensus. Nonetheless, in specifically defined
populations, e.g. European biopsy-naïve patients (average
csPCa prevalence of 25–40%), the percentage of PI-RADS 3
potentially is an indication of the ‘certainty’ of diagnosis and
thus of image quality and reading. Recent studies show that
differences of PI-RADS 3 rates (6–28%) are also attributable
to magnetic field strength (1.5 versus 3 T, thus image quality),
to strict adherence to the use of PI-RADS-assessment and of
expert double-reading [7–9, 19, 20].
Experience and training centres
There are scarce data that show a learning curve effect for
mpMRI, the effect of a dedicated reader education program
on PCa detection and diagnostic confidence and the effect of
an online interactive case-based interpretation program
[21–24]. Moreover, experienced urogenital radiologists show
higher inter-reader agreement and better area under the receiv-
er operating curve (AUC) characteristics as to radiologists
with lower levels of experience [25–29]. In a relatively small
sample size study, the AUC seems to remain stable after read-
ing 300 cases but is significantly lower in readers who have
read only 100 cases [27]. Nevertheless, thresholds for the
number of prostate mpMRIs required before independent
reporting and before reaching an expert level and the corre-
sponding number of cases per year are not yet well
established. Several previous studies suggested a dedicated
training course followed by ≥ 100 expert-supervised mpMRI
examinations [14, 22, 30]. For smaller centres or radiology
groups that want to start a prostate MRI program, there are
several existing (international) hands-on courses or possibili-
ties to arrange (online) supervised readings by expert centres
to facilitate this. The expert panel agreed that before
interpreting mpMRI in addition to the recommendations in
sections 1 and 2, a course should be attended, including the-
oretical and hands-on practice. Also, the expert panel listed a
set of criteria for ‘basic’ and ‘expert’ prostate radiologists
(Table 4). Radiologists should have read 100 supervised cases
before independent reporting, have read a minimum of 300
cases before being classified as a ‘basic’ prostate radiologist
and continue to read a minimum of 150 cases a year. For being
classified as an ‘expert’ prostate radiologist, a minimum num-
ber of 1000 cases should be read. Also, there should be an
examination every year for a novice prostate radiologist, and
5413Eur Radiol  (2020) 30:5404–5416
every 4 years for an expert. The panel did not reach a consen-
sus on the number of cases a year an expert prostate radiolo-
gist should read (200/≥ 500 cases).
Some limitations need to be recognized. One of the limita-
tions of a Delphi consensus process is that the results reflect
the opinions of a selection of experts and are not based on a
systematic literature review or meta-analyses. The methodol-
ogy captures what experts think, and not what the evidence
indicates in data-poor areas of practice. Also, definitions for
consensus are arbitrary, and other definitions could result in
different recommendations. The opinions of the expert panel
can represent the intuition of experienced, knowledgeable
practitioners who anticipate what the evidence would or will
show, but they also can be wrong. Conflicts of interest can
also influence expert opinion. However, as there are quite
many participants (44), the influence of these biases is likely
to be minimal. This modified Delphi process used a rigorous
methodology in which questions were carefully designed. The
consensus process and its results should be used for structur-
ing the discussions of important topics regarding prostate MR
image quality that currently lack evidence in the literature.
Because the questions addressed by the consensus are
highly relevant for daily clinical practice, we are careful to
emphasise that simply because experts agree does not mean
they are right. Nevertheless, this consensus contributes to our
knowledge. It captures what experts in the field think today
regarding the need to implement reliable, high-quality prostate
mpMRI as a diagnostic examination in the diagnostic pathway
of biopsy-naïve men at risk of csPCa. This consensus-based
statement should be used as a starting point, from where spe-
cific (reporting) templates will be developed, and future stud-
ies should be performed to validate the criteria and
recommendations.
Conclusion
This ESUR/ESUI consensus statement summarises in a struc-
tured way the opinions of recognized experts in diagnostic
prostate mpMRI issues that are not adequately addressed by
the existing literature. We focussed on recommendations on
image quality assessment criteria and prerequisites for acqui-
sition and reporting of mpMRI. Checking and reporting of
prostate MR image quality are mandatory. Initially, prostate
radiologists should have attended theoretical and hands-on
courses, followed by supervised education, and must perform
regular self- and external performance assessments, by com-
paring their diagnoses with histopathology outcomes.
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